Erratum: A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors (Proceedings of the National Academy of Sciences of the United States of America (10, 104 (4071-4076) DOI: 10.1073/pnas.0611693104);A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 10, 2007, Pages 4071-4076

  Scott, Andrew M ^a,b   Lee, Fook Thean ^a   Tebbutt, Niall ^a,b   Herbertson, Rebecca ^a   Gill, Sanjeev S ^a   Liu, Zhanqi ^a   Skrinos, Effie ^b   Murone, Carmel ^a,b   Saunder, Timothy H ^b   Chappell, Bridget ^b   Papenfuss, Anthony T ^c   Poon, Aurora M T ^a,b   Hopkins, Wendie ^a   Smyth, Fiona E ^a   MacGregor, Duncan ^a,b   Cher, Lawrence M ^b   Jungbluth, Achim A ^a   Brechbiel, Martin W ^d   Murphy, Roger ^a   Burgess, Antony W ^a   Hoffman, Eric W ^b   Johns, Terrance G ^a   Old, Lloyd J ^b   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti erbB1; Biodistribution; Immunotherapy; Tumor

Indexed keywords

ALKALINE PHOSPHATASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; LIGAND; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH806; MONOCLONAL ANTIBODY CH806 IN 111; MUTANT PROTEIN; RADIOISOTOPE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDIUM; MONOCLONAL ANTIBODY 806;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; APPETITE; AREA UNDER THE CURVE; ARTICLE; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LETHARGY; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WILD TYPE; CANCER TRANSPLANTATION; CELL MEMBRANE; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; INSTRUMENTATION; METABOLISM; METHODOLOGY; MIDDLE AGED; NEOPLASM; TUMOR CELL LINE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; FEMALE; HUMANS; IMMUNOTHERAPY; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 34247251270     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0708144104     Document Type: Erratum

References (42)

1. Rettig WJ, Old LJ (1989) Annu Rev Immunol 7:481-511.
2. Van den Eynde BJ, Scott AM (1998) in Encylopedia of Immunology, eds Roitt DPJ, Roitt IM (Academic, London), pp 2424-2431.
3. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al. (1997) Blood 90:2188-2195.
4. Baselga J, Artega CL (2005) J Clin Oncol 23:2445-2449.
5. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Arm Oncol 8:1197-1206.
6. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, et al. (1996) J Clin Oncol 14:737-744.
7. Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N, et al. (1990) J Clin Oncol 8:1894-1906.
8. Scott AM, Lee F-T, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, U P, Papenfuss A, et al. (2005) Clin Cancer Res 11:4810-4817.
9. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, et al. (1997) J Clin Oncol 15:1529-1537.
10. Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, Stockert E, Richards EC, Carr FJ, Harris WJ, et al. (2000) Cancer Res 60:3254-3261.
11. Scott AM, Lee F-T, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, et al. (2001) J Clin Oncol 19:3976-3987.
12. Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, Carswell EA, Cohen A, Larson SM, Old LJ (1994) J Clin Oncol 12:1193-1203.
13. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, et al. (2003) Clin Cancer Res 9:1639-1647.
14. Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Proc Natl Acad Sci USA 87:8602-8606.
15. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B (1987) Proc Natl Acad Sci USA 84:6899-6903.
16. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ (1994) Proc Natl Acad Sci USA 91:7727-7731.
17. Hills D, Rowlinson-Busza D, Gullick WJ (1995) Int J Cancer 63:537-543.
18. Sridhar SS, Seymour L, Shepherd FA (2003) Lancet Oncol 4:397-406.
19. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Clin Cancer Res 1:1311-1318.
20. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD (1990) Proc Natl Acad Sci USA 87:4207-4211.
21. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, et al. (2000) J Clin Oncol 18:904-914.
22. Graeven U, Kremer B, Sudhoff T, Kiling B, Rojo F, Weber D, Tillner J, Unal C, Schmiegel W (2006) Br J Cancer 94:1293-1299.
23. Ramos TC, Figueredo J, Catala M, Gonzales S, Selva JC, Cruz TM, Toldeo C, Silva S, Pestano Y, Ramos M, et al. (2006) Cancer Biol Ther 5:375-379.
24. Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, et al. (2002) Int J Cancer 98:398-408.
25. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TG, Scott AM, Gullick WJ, et al. (2003) Proc Natl Acad Sci USA 100:639-644.
26. Johns TG, Adams TE, Wittrup KD, Hall NE, Hoyne PA, Cochrane JR, Olsen MJ, Kim YS, Rothacker J, Nice EC, et al. (2004) J Biol Chem 279:30375-30384.
27. Johns TG, Mellman I, Cartwright GA, Ritter G, Old LJ, Burgess AW, Scott AM (2005) FASEB J 19:780-782.
28. Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM (2001) Cancer Res 61:5355-5361.
29. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, et al. (2003) Proc Natl Acad Sci USA 100:15871-15876.
30. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, et al. (2001) Cancer Res 61:5349-5354.
31. Perera RM, Narita Y, Furnari FB, Tavernasi ML, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, et al. (2005) Clin Cancer Res 11:6390-6399.
32. Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee F-T, Wang D, Kypridis A, Smyth FE, et al. (2005) Br J Cancer 92:1069-1077.
33. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, et al. (1991) J Natl Cancer Inst 83:97-104.
34. Baselga J (2001) Eur J Cancer 37(Suppl 4):S16-S22.
35. Gibson TB, Ranganathan A, Grothey A (2006) Clin Colorectal Cancer 6:29-31.
36. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, et al. (2004) J Clin Oncol 22:3003-3015.
37. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Polpin EA, Goodin S, Mauro D, Rubin EH (2006) Clin Cancer Res 12:6517-6522.
38. Lacouture AE (2006) Nat Rev Cancer 6:803-812.
39. Adams GP, Weiner LM (2005) Nat Biotechnol 23:1147-1157.
40. Liu Z, Panousis C, Smyth FE, Murphy R, Wirth V, Cartwright G, Johns TG, Scott AM (2003) Hybrid Hybridomics 22:219-228.
41. Stabin MG, Sparks RB, Crowe E (2005) J Nucl Med 46:1023-1027.
42. Ritter G, Cohen LS, Williams C, Jr, Richards EC, Old LJ, Welt S (2001) Cancer Res 61:685-6859.